tumeyes/iStock via Getty Images A phase 3 trial of Johnson & Johnson's ( NYSE: JNJ ) icotrokinra for plaque psoriasis met its co-primary endpoints: Psoriasis Area and Severity Index (PASI) 90 and Investigator’s Global Assessment ( IGA ). Topline results from the ICONIC-LEAD study showed that at week 16, patients.
Back to Health Page
